BERLIN -- Adding a test that predicts cancer signal origin to single standard of care (SoC) screening substantially increased ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced results from the randomized, double-blind, phase 3 ...

As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the immuno-oncology industry, ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it has been named ...

ClearNote Health, a company focused on improving early detection for some of the deadliest cancers, today announced a lineup of presentations at the European Society for Medical Oncology (ESMO) ...

(UroToday.com) The 2025 ESMO annual meeting featured a metastatic castration-resistant prostate cancer (mCRPC) session and a presentation by Dr. Channing Paller discussing germline and somatic genetic ...

Tecentriq reduced the risk of death by 41% and the risk of disease recurrence or death by 36% compared with placebo –– ...

Arc Institute, Gladstone Institutes, and University of California, San Francisco, scientists have developed an epigenetic ...

E. John Wherry, director of Penn's Colton Center for Autoimmunity, spoke with the Inquirer about the future of immunology ...

Women living near federally designated Superfund sites are more likely to develop aggressive breast cancer – including the hard-to-treat ...